
Health
pharmaceutical-regulation
fda-withdrawal
liquid-statin
Liquid Statin FloLipid Faces Possible FDA Withdrawal Over Missed Reports, Leaving Patients Who Can't Swallow Pills Weighing Options
Medical Daily
•
Thursday, November 19, 2026
•
United States
The Food and Drug Administration has proposed withdrawing approval of FloLipid, a liquid form of the cholesterol drug simvastatin, because its maker "has repeatedly failed to file required annual reports." Patients who cannot swallow pills should seek guidance before switching treatments.
Sources (1)
Medical Daily
Thursday, November 19, 2026